NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®)

NCCN Guidelines® recommend inotuzumab ozogamicin as a treatment option for adults with relapsed or refractory B-cell precursor ALL1

  • BESPONSA is indicated for the treatment of adults with relapsed or refractory B-cell precursor ALL2

ALL=acute lymphoblastic leukemia; Ph=Philadelphia chromosome; TKI=tyrosine kinase inhibitor.

  1. Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.1.2018. © 2018 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  2. BESPONSA Prescribing Information. New York, NY: Pfizer Inc.